{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:18:12Z","timestamp":1794057492998,"version":"4.8.0"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Relevant literature was retrieved from the PubMed database, Embase database, Cochrane Library database, etc. The search period is from the establishment of the database to January 2022. The outcomes include clinical symptoms, improvement in biochemistry, improvement in intestinal microbiota, improvement in the immune system, and adverse events. Literature screening and data extraction were independently carried out by two researchers according to the inclusion and exclusion criteria, and RevMan 5.3 software was used for statistics and analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, a total of 14 randomized controlled trials (RCTs) involving six types of autoimmune diseases were included. The results showed the following. 1) Type 1 diabetes mellitus (T1DM): compared with the autologous fecal microbiota transplantation (FMT) group (control group), the fasting plasma C peptide in the allogenic FMT group at 12 months was lower. 2) Systemic sclerosis: at week 4, compared with one of two placebo controls, three patients in the experimental group reported a major improvement in fecal incontinence. 3) Ulcerative colitis, pediatric ulcerative colitis, and Crohn\u2019s disease: FMT may increase clinical remission, clinical response, and endoscopic remission for patients with ulcerative colitis and increase clinical remission for patients with Crohn\u2019s disease. 4) Psoriatic arthritis: there was no difference in the ratio of ACR20 between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on current evidence, the application of FMT in the treatment of autoimmune diseases is effective and relatively safe, and it is expected to be used as a method to induce remission of active autoimmune diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021235055<\/jats:uri>, identifier CRD42021235055.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.944387","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T12:15:40Z","timestamp":1664540140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Liuting","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: A comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv292","article-title":"Prediction and prevention of autoimmune disease in the 21st century: A review and preview","volume":"183","author":"Rose","year":"2016","journal-title":"Am J Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.36562","article-title":"Long noncoding RNAs in autoimmune diseases","volume":"107","author":"Xu","year":"2019","journal-title":"J BioMed Mater Res A"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318173e10e","article-title":"Organ-specific \u201cautoimmune\u201d disease","volume":"43","author":"Quinn","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102421","article-title":"Systemic autoinflammatory diseases","volume":"109","author":"Krainer","year":"2020","journal-title":"J Autoimmun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129364","article-title":"Targeting medication non-adherence behavior in selected autoimmune diseases: A systematic approach to digital health program development","volume":"10","author":"van Mierlo","year":"2015","journal-title":"PloS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","article-title":"Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases","volume":"33","author":"Cooper","year":"2009","journal-title":"J Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.001","article-title":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","volume":"64","author":"Yasunaga","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.103235","article-title":"The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review","volume":"44","author":"Chandrashekara","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: Non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S172836","article-title":"Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study","volume":"14","author":"Akhlaghi","year":"2018","journal-title":"Ther Clin Risk Manage"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2021.306","article-title":"Safety of long-term use of four common conventional disease modifying anti-rheumatic drugs in rheumatoid arthritis","volume":"51","author":"Kedia","year":"2021","journal-title":"J R Coll Phys Edinb"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.02.044","article-title":"The human gut microbiome: From association to modulation","volume":"172","author":"Schmidt","year":"2018","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.09.004","article-title":"The gut microbiota at the service of immunometabolism","volume":"32","author":"Michaudel","year":"2020","journal-title":"Cell Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.08.002","article-title":"Pursuing human-relevant gut microbiota-immune interactions","volume":"51","author":"Spencer","year":"2019","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41575-022-00581-2","article-title":"Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders","volume":"19","author":"Metwaly","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.04.001","article-title":"The gut microbiota: Emerging evidence in autoimmune diseases","volume":"26","author":"Zhang","year":"2020","journal-title":"Trends Mol Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nm.3914","article-title":"The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.98","article-title":"Understanding the mechanisms of faecal microbiota transplantation","volume":"13","author":"Khoruts","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803103","article-title":"Fecal microbiota transplantation for primary clostridium difficile infection","volume":"378","author":"Juul","year":"2018","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.08.011","article-title":"Fecal microbiota transplantation: Review and update","volume":"118","author":"Wang","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2020.1854640","article-title":"Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: A systematic review and meta-analysis","volume":"12","author":"Green","year":"2020","journal-title":"Gut Microbes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2017.1290757","article-title":"Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease","volume":"8","author":"Weingarden","year":"2017","journal-title":"Gut Microbes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2016.09.012","article-title":"Fecal microbiota transplantation","volume":"46","author":"Vindigni","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06090-z","article-title":"Microbial-based and microbial-targeted therapies for inflammatory bowel diseases","volume":"65","author":"Oka","year":"2020","journal-title":"Dig Dis Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.16148","article-title":"Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020","volume":"53","author":"Marcella","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B31","article-title":"Chapter 8: assessing risk of bias in included studies","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.1.0","author":"Deeks","year":"2020"},{"key":"B32","article-title":"Chapter 9: Analyzing data and undertaking meta-analyses","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks","year":"2020"},{"key":"B33","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2020"},{"key":"B34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.chom.2020.03.006","article-title":"Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative colitis","volume":"27","author":"Leonardi","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/cei.13397","article-title":"Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease","volume":"199","author":"Quraishi","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.16286\/j.1003-5052.2017.06.045","article-title":"Fecal bacteria transplantation combined with mesalazine in the treatment of ulcerative colitis","volume":"32","author":"Chen","year":"2017","journal-title":"China Urban Rural Enterprise Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000497042","article-title":"Combined endoscopic and oral fecal microbiota transplantation in patients with antibiotic-dependent pouchitis: Low clinical efficacy due to low donor microbial engraftment","volume":"4","author":"Herfarth","year":"2019","journal-title":"InflammIntest Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12866-016-0869-2","article-title":"Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora","volume":"16","author":"Wei","year":"2016","journal-title":"BMC Microbiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05751-y","article-title":"Fecal microbiota transplant via endoscopic delivering through small intestine and colon: No difference for crohn\u2019s disease","volume":"65","author":"Yang","year":"2020","journal-title":"Dig Dis Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/gutjnl-2020-322630","article-title":"Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial","volume":"70","author":"de Groot","year":"2021","journal-title":"Gut"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232739","article-title":"Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial","volume":"15","author":"Fretheim","year":"2020","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2015.03.045","article-title":"Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis","volume":"149","author":"Rossen","year":"2015","journal-title":"Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20046","article-title":"Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial","volume":"321","author":"Costello","year":"2019","journal-title":"JAMA"},{"key":"B46","first-page":"897","article-title":"A clinical study on fecal bacteria transplantation combined with mesalazine in the treatment of ulcerative colitis with damp-heat type of large intestine","volume":"26","author":"Sun","year":"2018","journal-title":"Chin J Integrated Traditional Chin Western Med"},{"key":"B47","article-title":"Efficacy observation of fecal bacterial transplantation in mild to moderate ulcerative colitis of left colon","volume":"32","author":"Deng","year":"2020","journal-title":"Clin J Digestive Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00400-3","article-title":"Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): A randomised, double-blind, placebo-controlled trial","volume":"7","author":"Haifer","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12876-021-01856-9","article-title":"Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: Results of a single-center, prospective, randomized pilot study","volume":"21","author":"Crothers","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40168-020-0792-5","article-title":"Fecal microbiota transplantation to maintain remission in crohn\u2019s disease: a pilot randomized controlled study","volume":"8","author":"Sokol","year":"2020","journal-title":"Microbiome"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz060","article-title":"Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: A pilot study","volume":"13","author":"Sood","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1053\/j.gastro.2021.04.067","article-title":"McMaster pediatric fecal microbiota transplant research collaboration. results of the first pilot randomized controlled trial of fecal microbiota transplant in pediatric ulcerative colitis: Lessons, limitations, and future prospects","volume":"161","author":"Pai","year":"2021","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219511","article-title":"Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial","volume":"80","author":"Kragsnaes","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.10.005","article-title":"Role of the intestinal microbiome in autoimmune diseases and its use in treatments","volume":"339","author":"Marietta","year":"2019","journal-title":"Cell Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.12765","article-title":"Intestinal dysbiosis and probiotic applications in autoimmune diseases","volume":"152","author":"de Oliveira","year":"2017","journal-title":"Immunology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cei.13158","article-title":"The microbiome in autoimmune diseases","volume":"195","author":"De Luca","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1916278","article-title":"Alcohol as friend or foe in autoimmune diseases: a role for gut microbiome","volume":"13","author":"Caslin","year":"2021","journal-title":"Gut Microbes"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000628","article-title":"Microbiome and autoimmune diseases: cause and effect relationship","volume":"31","author":"Nogueira","year":"2019","journal-title":"CurrOpinRheumatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2018.1517044","article-title":"Microbial modulation of the gut microbiome for treating autoimmune diseases","volume":"12","author":"Balakrishnan","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0367-2","article-title":"Host-microbiota interactions in immune-mediated diseases","volume":"18","author":"Ruff","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.04.008","article-title":"Homeostatic immunity and the microbiota","volume":"46","author":"Belkaid","year":"2017","journal-title":"Immun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-093019-112348","article-title":"Control of immunity by the microbiota","volume":"39","author":"Ansaldo","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7201","article-title":"Translocation of a gut pathobiont drives autoimmunity in mice and humans","volume":"359","author":"Manfredo Vieira","year":"2018","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"102360","DOI":"10.1016\/j.jaut.2019.102360","article-title":"Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis","volume":"107","author":"Zhou","year":"2020","journal-title":"J Autoimmun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2005.01575.x","article-title":"Candida albicans cell-wall fraction exacerbates collagen-induced arthritis in mice","volume":"61","author":"Yordanov","year":"2005","journal-title":"Scand J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93450","article-title":"Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints","volume":"127","author":"Pianta","year":"2017","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/art.39783","article-title":"Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine","volume":"68","author":"Maeda","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.673708","article-title":"Partners in leaky gut syndrome: Intestinal dysbiosis and autoimmunity","volume":"12","author":"Kinashi","year":"2021","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00585-3","article-title":"The gut-joint axis in rheumatoid arthritis","volume":"17","author":"Zaiss","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5145","article-title":"The role of the gut microbiome in systemic inflammatory disease","volume":"360","author":"Clemente","year":"2018","journal-title":"BMJ"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2020.1792040","article-title":"Fecal microbiota transplantation for ulcerative colitis","volume":"44","author":"Matsuoka","year":"2021","journal-title":"Immunol Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001075","article-title":"Fecal microbiota transplantation: The evolving risk landscape","volume":"116","author":"Gupta","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.7150\/thno.44113","article-title":"Depletion of the diabetic gut microbiota resistance enhances stem cells therapy in type 1 diabetes mellitus","volume":"10","author":"Lv","year":"2020","journal-title":"Theranostics"},{"key":"B76","doi-asserted-by":"publisher","first-page":"12098","DOI":"10.1038\/s41598-020-69001-2","article-title":"Chloroquine as a promising adjuvant therapy for type 1 diabetes mellitus","volume":"10","author":"de Almeida J\u00fanior","year":"2020","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.2","article-title":"Immune modulation in humans: implications for type 1 diabetes mellitus","volume":"10","author":"Roep","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00248","article-title":"Prediction and prevention of type 1 diabetes","volume":"11","author":"Primavera","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4942-x","article-title":"Early-life factors contributing to type 1 diabetes","volume":"62","author":"Craig","year":"2019","journal-title":"Diabetologia"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.109873","article-title":"Investigation of gut microbiome changes in type 1 diabetic mellitus rats based on high-throughput sequencing","volume":"124","author":"Ma","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111843","article-title":"Gastrointestinal microbiota and type 1 diabetes mellitus: The state of art","volume":"8","author":"Durazzo","year":"2019","journal-title":"J Clin Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/07853890.2016.1222449","article-title":"Is there a role for gut microbiota in type 1 diabetes pathogenesis","volume":"49","author":"Bibb\u00f2","year":"2017","journal-title":"Ann Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12915","article-title":"Current understanding of the role of gut dysbiosis in type 1 diabetes","volume":"11","author":"Abdellatif","year":"2019","journal-title":"J Diabetes"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0620-2","article-title":"The human gut microbiome in early-onset type 1 diabetes from the TEDDY study","volume":"562","author":"Vatanen","year":"2018","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e0183786","DOI":"10.1371\/journal.pone.0183786","article-title":"Maternal treatment with short-chain fatty acids modulates the intestinal microbiota and immunity and ameliorates type 1 diabetes in the offspring","volume":"12","author":"Needell","year":"2017","journal-title":"PloS One"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01733","article-title":"Modulation of gut microbiota by low methoxyl pectin attenuates type 1 diabetes in non-obese diabetic mice","volume":"10","author":"Wu","year":"2019","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4910-5","article-title":"Targeting gut microbiota and barrier function with prebiotics to alleviate autoimmune manifestations in NOD mice","volume":"62","author":"Hansen","year":"2019","journal-title":"Diabetologia"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00481","article-title":"Effect of prebiotic on microbiota, intestinal permeability, and glycemic control in children with type 1 diabetes","volume":"104","author":"Ho","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa407","article-title":"Gut microbiota in T1DM-onset pediatric patients: Machine-learning algorithms to classify microorganisms as disease linked","volume":"105","author":"Biassoni","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.107449","article-title":"Bacteroidetes and firmicutes levels in gut microbiota and effects of hosts TLR2\/TLR4 gene expression levels in adult type 1 diabetes patients in Istanbul, Turkey","volume":"34","author":"Demirci","year":"2020","journal-title":"J Diabetes Complications"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-46","article-title":"Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study","volume":"11","author":"Murri","year":"2013","journal-title":"BMC Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12243","article-title":"Differences in the gut microbiota of healthy children and those with type 1 diabetes","volume":"56","author":"Soyucen","year":"2014","journal-title":"Pediatr Int"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.000412","article-title":"The intestinal proteome of diabetic and control children is enriched with different microbial and host proteins","volume":"163","author":"Pinto","year":"2017","journal-title":"Microbiol (Reading)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0526","article-title":"Fecal microbiota composition differs between children with \u03b2-cell autoimmunity and those without","volume":"62","author":"de Goffau","year":"2013","journal-title":"Diabetes"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.182841","article-title":"Imbalance of fecal microbiota at newly diagnosed type 1 diabetes in Chinese children","volume":"129","author":"Qi","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.04.032","article-title":"Gut microbiota profiling in han Chinese with type 1 diabetes","volume":"141","author":"Huang","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2019.80.9.530","article-title":"Systemic sclerosis","volume":"80","author":"Hughes","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa680","article-title":"Epidemiology of systemic sclerosis in the UK: an analysis of the clinical practice research datalink","volume":"60","author":"Pauling","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/art.39572","article-title":"Association of systemic sclerosis with a unique colonic microbial consortium","volume":"68","author":"Volkmann","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000134","article-title":"Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts","volume":"4","author":"Volkmann","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-016-1182-z","article-title":"Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease","volume":"18","author":"Andr\u00e9asson","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"B104","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis.","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","article-title":"Gut microbiome structure and metabolic activity in inflammatory bowel disease","volume":"4","author":"Franzosa","year":"2019","journal-title":"Nat Microbiol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12849","article-title":"Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment","volume":"21","author":"Guo","year":"2020","journal-title":"J Dig Dis"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611256","article-title":"The IL23-IL17 immune axis in the treatment of ulcerative colitis: Successes, defeats, and ongoing challenges","volume":"12","author":"Noviello","year":"2021","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2021.06.024","article-title":"Mucosal biofilms are an endoscopic feature of irritable bowel syndrome and ulcerative colitis","volume":"161","author":"Baumgartner","year":"2021","journal-title":"Gastroenterology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01208","article-title":"Preparing the gut with antibiotics enhances gut microbiota reprogramming efficiency by promoting xenomicrobiota colonization","volume":"8","author":"Ji","year":"2017","journal-title":"Front Microbiol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.004","article-title":"Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis","volume":"160","author":"Galipeau","year":"2021","journal-title":"Gastroenterol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090168","article-title":"Probiotics","volume":"67","author":"Williams","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111638","article-title":"Effects of low and high FODMAP diets on human gastrointestinal microbiota composition in adults with intestinal diseases: A systematic review","volume":"8","author":"Vandeputte","year":"2020","journal-title":"Microorganisms"},{"key":"B116","article-title":"Fecal microbiota transplantation in ulcerative colitis","volume":"82","author":"Blanchaert","year":"2019","journal-title":"Acta Gastroenterol Belg"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.3390\/ijms21072582","article-title":"Recent advances in psoriasis research;the clue to mysterious relation to gut microbiome","volume":"21","author":"Komine","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.006","article-title":"Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine","volume":"44","author":"Haghikia","year":"2016","journal-title":"lmmunity"},{"key":"B122","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41467-017-02490-4","article-title":"Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss","volume":"9","author":"Lucass","year":"2018","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3713","article-title":"Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes","volume":"18","author":"Marino","year":"2017","journal-title":"Nat Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2013.05.013","article-title":"A single strain of clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis inmice","volume":"13","author":"Hayashi","year":"2013","journal-title":"Cell Host Microbe"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7569431","article-title":"Oral probiotic VSL 3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase enriched tolerogenic intestinal environment","volume":"2016","author":"Dolpady","year":"2016","journal-title":"J Diabetes Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"75","DOI":"10.12688\/f1000research.7411.1","article-title":"Beta cell antigens in type 1 diabetestriggers in pathogenesis and therapeutic targets","volume":"5","author":"Mauvais","year":"2016","journal-title":"F1000Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06340.x","article-title":"Type 1 diabetes: role of intestinal microbiome in humans and mice","volume":"1243","author":"Boerner","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2015.2757","article-title":"TEDDY study group. association of early exposure of probiotics and islet autoimmunity in the TEDDY study","volume":"170","author":"Uusitalo","year":"2016","journal-title":"JAMA Pediatr"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017178","article-title":"Effects of lactobacllusrhamnosus GG and bifidobacterium lactis Bb12 on beta-cell function in children with newlydiagnosed type 1 diabetes: protocol of a randomised controlled trial","volume":"7","author":"Groele","year":"2017","journal-title":"BMJ Open"},{"key":"B130","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1017\/S0007114510003363","article-title":"Prebioticefects:metabolic and health benefits","volume":"104","author":"Roberfroid","year":"2010","journal-title":"Br J Nut"},{"key":"B131","article-title":"Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes:a prospective cohort study","volume":"20","author":"Harbison","year":"2019","journal-title":"Pediatr Diabetes"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/janaerobe.2011.03.018","article-title":"Effect of banana consumption on faecalmicrobiota:arandomised,controlled trial","volume":"17","author":"Mitsou","year":"2011","journal-title":"Anaerobe"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-10749-y","article-title":"Lactobacillus salivarius LI01 encapsulated in alginate-pectin microgels ameliorates d-galactosamine-induced acute liver injury in rats","volume":"104","author":"Zhuge","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1831-2","article-title":"Oral probiotic administration induces interleukin- 10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse","volume":"48","author":"Calcinaro","year":"2005","journal-title":"Diabetologia"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102938","article-title":"Analysis of gut microbiota in rheumatoid arthritis patients: disease-related dysbiosis and modifications induced by etanercept","volume":"19","author":"Picchianti-Diamanti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030431","article-title":"Molecular insight into gut microbiota and rheumatoid arthritis","volume":"17","author":"Wu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12379","article-title":"Mechanisms involved in triggering rheumatoid arthritis","volume":"269","author":"Catrina","year":"2016","journal-title":"Immunol Rev"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.06.001","article-title":"Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells","volume":"32","author":"Wu","year":"2010","journal-title":"Immun"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220687","article-title":"Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese","volume":"80","author":"Tomofuji","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-017-8906-2","article-title":"The microbiome and systemic lupus erythematosus","volume":"65","author":"Katz-Agranov","year":"2017","journal-title":"Immunol Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/srep24072","article-title":"Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients","volume":"6","author":"L\u00f3pez","year":"2016","journal-title":"Sci Rep"},{"key":"B142","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2019.11.003","article-title":"The microbiome and inflammatory bowel disease","volume":"145","author":"Glassner","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat Metab"},{"key":"B144","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1631\/jzus.B1900075","article-title":"Changes in peripheral blood inflammatory factors (TNF-\u03b1 and IL-6) and intestinal flora in AIDS and HIV-positive individuals","volume":"20","author":"Lu","year":"2019","journal-title":"J Zhejiang Univ Sci B"},{"key":"B145","article-title":"Studies on the population of Th17 and treg cells and the expression of the correlated cytokines in SLE patients","volume":"19","author":"Li","year":"2015","journal-title":"Chin J Lab Diagnosis"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-009-9365-x","article-title":"Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity","volume":"30","author":"Chen","year":"2010","journal-title":"J Clin Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102844","article-title":"Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial","volume":"130","author":"Huang","year":"2022","journal-title":"J Autoimmun"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2019.03.010","article-title":"Meta-analysis of fecal microecological transplantation in the treatment of ulcerative colitis","volume":"58","author":"Mo","year":"2019","journal-title":"Chin J Internal Med"},{"key":"B149","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coph.2019.04.008","article-title":"The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications","volume":"49","author":"Dailey","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-018-0541-8","article-title":"Microbiota transplantation: concept, methodology and strategy for its modernization","volume":"9","author":"Zhang","year":"2018","journal-title":"Protein Cell"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz006","article-title":"Enterotoxigenic clostridium perfringens infection as an adverse event after faecal microbiota transplantation in two patients with ulcerative colitis and recurrent clostridium difficile infection: A neglected agent in donor screening","volume":"13","author":"Azimirad","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0800-3","article-title":"The safety of fecal microbiota transplantation for crohn\u2019s disease: Findings from a long-term study","volume":"35","author":"Wang","year":"2018","journal-title":"Adv Ther"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00809-2","article-title":"Long-term safety and efficacy of fecal microbiota transplant in active ulcerative colitis","volume":"42","author":"Ding","year":"2019","journal-title":"Drug Saf"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-105205","article-title":"Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota","volume":"4","author":"Peng","year":"2016","journal-title":"Endosc Int Open"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy266","article-title":"The microbial composition of bacteroidetes species in ulcerative colitis is effectively improved by combination therapy with fecal microbiota transplantation and antibiotics","volume":"24","author":"Ishikawa","year":"2018","journal-title":"Inflammation Bowel Dis"},{"key":"B156","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3969\/j.issn.1000-1174.2015.09.001","article-title":"Clinical study of single fecal flora transplantation in the treatment of ulcerative colitis (report of 7 cases)","volume":"35","author":"Mo","year":"2015","journal-title":"Chin J Anorectal Dis"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2015.05.007","article-title":"Preliminary study of fecal microecological transplantation in the treatment of ulcerative colitis","volume":"54","author":"Ren","year":"2015","journal-title":"Chin J Internal Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.123","article-title":"Pretreatment with antibiotics may enhance the efficacy of fecal microbiota transplantation in ulcerative colitis: a meta-analysis","volume":"10","author":"Keshteli","year":"2017","journal-title":"Mucosal Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.944387\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T12:15:58Z","timestamp":1664540158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.944387\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":158,"alternative-id":["10.3389\/fimmu.2022.944387"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.944387","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"944387"}}